

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

**歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

### **PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION**

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

On 9 May 2024, in order to, among other things, reflect and align with requirements under the Listing Rules in light of the expansion of the paperless listing regime and electronic dissemination of corporate communications, as well as changes in regulatory requirements concerning mandatory provisions for PRC issuers listed overseas, the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company proposed to put forward a special resolution to amend the existing articles of association of the Company (the “**Articles of Association**”) to the shareholders of the Company (the “**Shareholder(s)**”) for approval at the forthcoming annual general meeting of the Company (the “**2023 AGM**”).

The proposed amendments to the existing Articles of Association (the “**Proposed Amendments**”) mainly relate to the dissemination of corporate communications, removal of mandatory provisions which are no longer required, changes in share capital and housekeeping matters. Full version of the Proposed Amendments will be set out in the circular to be dispatched to the Shareholders. The Board is of the view that the Proposed Amendments are in the interests of the Company and the Shareholders as a whole.

The Proposed Amendments are subject to the approval of the Shareholders by way of special resolution at the 2023 AGM and, if approved, will become effective upon such approval. A special resolution will also be proposed at the 2023 AGM for the Shareholders to consider and approve the reduction of the registered capital of the Company. Prior to the passing of the relevant special resolutions at the 2023 AGM, the existing Articles of Association shall remain valid.

After the Proposed Amendments come into effect, the full text of the revised Articles of Association will be published on the Company's website (<http://www.zyloxtb.com>) and the Stock Exchange's website ([www.hkexnews.hk](http://www.hkexnews.hk)).

A circular containing, among other things, full version of the Proposed Amendments together with the notice of the 2023 AGM will be dispatched to the Shareholders in due course.

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, 9 May 2024

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.*